ZM39923| CAS 273727-89-2

Cas No.:	273727-89-2
Chemical Name:	3-benzyl(propan-2-yl)amino-1-(naphthalen-2-yl)propan-1-one
Synonyms:	1-Propanone,3-[(1-methylethyl)(phenylmethyl)amino]-1-(2-naphthalenyl)-;2-naphtyl 2-(N-isopropyl-N-benzylamino)ethyl ketone;ZM-39923;1-Propanone,3-[(1-methylethyl)(phenylmethyl)amino]-1-(2-naphthalenyl);2-(N-isopropylbenzyl)aminoethyl-2-naphthylketone;3-(benzyl(isopropyl)amino)-1-(naphthalen-2-yl)propan-1-one;ZM39923;3-benzyl(propan-2-yl)amino-1-(naphthalen-2-yl)propan-1-one;NCGC00025126-02;UNII-M0ZX82000S;Lopac-Z-4626;3-((1-Methylethyl)(phenylmethyl)amino)-1-(2-naphthalenyl)-1-propanone;NCGC00016107-09;M0ZX82000S;Lopac0_000844;3-[benzyl(propan-2-yl)amino]-1-naphthalen-2-ylpropan-1-one;DTXSID701017205;1-Propanone, 3-[(1-methylethyl)(phenylmethyl)amino]-1-(2-naphthalenyl)-;NCGC00016107-01;NCGC00016107-04;3-[benzyl(isopropyl)amino]-1-(2-naphthyl)propan-1-one;HSCI1_000104;NCGC00016107-02;NCGC00016107-03;CHEMBL596674;EN300-18749151;3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one;SDCCGSBI-0050820.P003;jak3 inhibitor iv;BRD-K40624912-003-02-3;A913285;3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one;ZM 39923;1-Propanone, 3-((1-methylethyl)(phenylmethyl)amino)-1-(2-naphthalenyl)-;GTPL5994;SCHEMBL2891331;AKOS030526763;CHEBI:92715;HY-12589A;NCGC00025126-01;CCG-204927;NCGC00016107-14;273727-89-2;CS-4952;BDBM81346;JSASWRWALCMOQP-UHFFFAOYSA-N;NCGC00016107-05;Tocris-1367;FT-0723801;M9440 (Me-3,4-dephostatin)
SMILES:	O=C(C1=CC=C2C=CC=CC2=C1)CCN(C(C)C)CC3=CC=CC=C3
Formula:	C₂₃H₂₅NO
M.Wt:	331.4507
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1, also potently inhibits human tissue transglutaminase (TGM2) with IC50 of 10 nM; ZM39923 is less potent for EGFR, JAK1 and CDK4 with pIC50 of 5.6, 4.4 and < 5.0, no activity fgor JAK2; alteres TGM2 activity in polyglutamine-expressing Drosophila model of neurodegeneration and is found to improve survival; significantly attenuates CCR7-induced Jak3 phosphorylation in metastatic SCCHN cells.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.